U.S. pharma giant copyright scrapped two experimental weight loss tablets final year—a as soon as-day by day capsule, lotiglipron, as a consequence of elevated liver enzymes in addition to a two times-daily tablet, danuglipron, as a consequence of robust side effects—but CEO Albert Bourla has stated the company is determined to “Participate i